MYGN Financial Facts
Net income: -1.2MMolecular diagnostic testing: 165.1M
See Full Income Statement
Total current liabilities: 274.9M
Net equipment and leasehold improvements: 56.8M
See Full Balance Sheet
Myriad Genetics Inc. (MYGN) Earnings
|
Expand Research on MYGN
| Next EPS Date | 11/3/26 *Est. | EPS Growth Rate | -600.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +13.7% | Revenue Growth Rate | -10.5% *Last Qtr. |
| Average % Move 1-Wk after EPS | -16.5% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7/30/26 | Q226 | -$0.25 | -$0.06 | -$0.19 | $190.7M | $206.03M | = |  | | Details | |
| 5/5/26 | Q126 | -$0.09 | -$0.07 | -$0.02 | $200.4M | $202.39M | = | | | Details | |
| 2/23/26 | Q425 | $0.04 | -$0.02 | +$0.06 | $209.8M | $207.17M | = | | | Details | |
| 11/3/25 | Q325 | $0.00 | -$0.01 | +$0.01 | $205.7M | $204.97M | = | | | Details | |
| 8/5/25 | Q225 | $0.05 | -$0.01 | +$0.06 | $213.1M | $201.91M | = | | | Details | |
| 5/6/25 | Q125 | -$0.03 | -$0.06 | +$0.03 | $195.9M | $200.9M | = | | | Details | |
| 2/24/25 | Q424 | $0.03 | $0.03 | $0.00 | $211M | $213.31M | = | | | Details | |
| 11/7/24 | Q324 | $0.06 | $0.02 | +$0.04 | $213.3M | $210.76M | = | | | Details |
